AMENDMENTS TO THE CLAIMS:

The listing of the claims which follows replaces any and all prior versions and/or listings of the claims in the application.

1. **(Presently amended)** A compound represented by chemical formula (I) or a pharmaceutically acceptable salt thereof:





(I)

wherein

~~A is N, or CH~~;

B is -C_{1-6}alkyl-, -C_{0-3}alkyl-O-C_{0-3}alkyl-, -C_{0-3}alkyl-NH-C_{0-3}alkyl-, -C_{0-3}alkyl-S-C_{0-3}alkyl-, -C_{0-3}alkyl-PH-C_{0-3}alkyl-, -C_{0-3}alkyl-C(O)-C_{0-3}alkyl-, or a direct bond;

X is -C_{1-6}alkyl-, -C_{0-3}alkyl-O-C_{0-3}alkyl-, -C_{0-3}alkyl-NH-C_{0-3}alkyl-, -C_{0-3}alkyl-S-C_{0-3}alkyl-, -C_{0-3}alkyl-PH-C_{0-3}alkyl-, -C_{0-3}alkyl-C(O)-C_{0-3}alkyl-, or a direct bond;

~~D is C or N;~~

~~E is N, O, NH, CH_2, or CH;~~

R, R^{71}, and R^{72} each independently is hydrogen, OH, -C_{0-4}alkyl-O-C_{0-4}alkyl-, -C_{0-4}alkyl-C(O)-C_{0-4}alkyl-, -C_{0-4}alkyl-C(O)-O-C_{0-4}alkyl-, or C_{1-4}alkyl, any alkyl optionally substituted with 1-6 groups, each group independently being –OH, -NH_2, -NH-CH_3, -$N(CH_3)_2$, or halogen;

n is 1, 2, 3, or 4;

m is 0, 1, 2, 3, or 4;

n+m is 2, 3, 4, 5, or 6; optionally, one of n CH_2 and one of m CH_2 are bridged by a –C_{0-2}alkyl- linkage;

E^1 is CH, N, or CR^6;

E^2 is CH2, CHR, NH, NR, O, S, -S(O)-, or -S(O)2-;

R^1 is halogen or C_{1-4}alkyl;

R^2, R^3, R^4, and R^6 are each independently halogen, C_{1-4}alkyl, or hydrogen; and

R^5 is H, CH_3, or CH_2CH_3.

2. **(Canceled)**

3. **(Canceled)**

4. **(Presently amended)** The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

~~A is N;~~

~~D is C;~~

~~E is NH; and~~
X is -C_{0-3}alkyl-S-C_{0-3}alkyl-.

5. (**Presently amended**) The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein
~~A is N;~~
~~D is C;~~
~~E is NH;~~
X is -C_{0-3}alkyl-S-C_{0-3}alkyl-; and
B is a direct bond.

6. (**Original**) The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein
E^1 is N; and
E^2 is NR.

7. (**Original**) The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein
E^1 is N;
E^2 is NR; and
one of n CH_2 and one of m CH_2 are bridged by a –C_{0-2}alkyl– linkage.

8. (**Original**) The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein
E^1 is N; and
E^2 is O.

9. (**Original**) The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein
E^1 is N; and
E^2 is CHR.

10. (**Presently amended**) The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

~~A is N;~~

~~D is C;~~

~~E is NH;~~

X is -C_{0-3}alkyl-S-C_{0-3}alkyl-; and

B is NH.

11. (**Original**) The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein

E^1 is CH; and

E^2 is NR.

12. (**Presently amended**) The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

~~A is N;~~

~~D is C;~~

~~E is NH;~~

X is -C_{0-3}alkyl-S-C_{0-3}alkyl-; and

B is -C_{0-3}alkyl-O-C_{0-3}alkyl-

13. (**Presently amended**) The compound according to claim 1, represented by





or a pharmaceutically acceptable salt thereof.

14. (**Original**) A pharmaceutical composition comprising an inert carrier and an effective amount of a compound according to claim 1.

15. to 18. (**Canceled**)